Encellin Closes $9.9M Financing Led by Khosla Ventures to Advance Cell Encapsulation Platform for En
Summary
The technology can be used in a variety of different indications, beginning with chronic endocrine disorders, said Crystal Nyitray, Ph.D., CEO & Co-Founder, Encellin. Using advanced nanotechnology and bioengineering, we have developed biocompatible materials into permeable, soft pouches designed to support cell function. We look forward to advancing the use of our EnCRT loaded with primary islet to enable responsive insulin delivery for patients with high risk T1D.The cell is essentially a nanorobotics-based machine. Encellin has developed a technology that safeguards implanted cells and transforms them into programmable molecular factories in the body, releasing therapies when needed, said Alex Morgan, Partner, Khosla Ventures. Encellins team includes leading experts in biomaterials, medical devices, and cell therapies with a track record of successful biotech IPOs and commercial programs.